other material
confidence high
sentiment negative
materiality 0.65
Protagenic Therapeutics delays PT00114 trial start to Jan 2022; Q2 net loss $2.6M
Protagenic Therapeutics, Inc.new
- FDA required ready-to-inject vials; IND re-filing moved to Q4 2021, Phase I/IIa start to Jan 2022.
- Q2 2021 net loss $2.6M (vs $0.6M in Q2 2020); G&A expense rose to $2.2M.
- Closed $13.2M public offering of 3.18M units at $4.15/unit; cash $11.9M as of June 30, 2021.
- Initial Phase I/IIa data readout expected 1H 2022, final readout Q3 2022.